Capmatinib
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Tepmetko · Tepo
MET inhibitor · approved 2021 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A once-daily MET inhibitor — blood creatinine rise and peripheral edema are its hallmark, manageable effects.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Blood creatinine increase and peripheral edema are the main treatment-related adverse events in the VISION program: in the 255-patient METex14 safety analysis, all-cause creatinine increase occurred in 25.9% and edema — the most common adverse event of clinical interest — in 69.8%. Both are generally mild to moderate and manageable, rarely leading to discontinuation.Source: Veillon et al., Clin Lung Cancer 2022 (VISION safety, creatinine increase 25.9%); Ahn et al., Clin J Oncol Nurs 2022
Occurs early, within the first treatment cycles.
Distilled from: “Early — within the first cycles.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
MET-inhibitor pseudo-AKI: serum creatinine rose during therapy while cystatin C remained stable, indicating inhibition of renal tubular transporters rather than a GFR fall; creatinine settled on dose reduction (case-documented). PMID 41710007 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Highly selective oral MET inhibitor; approved for NSCLC with MET exon 14 skipping alterations.
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Apr 2025) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage modification is recommended in patients with mild or moderate renal impairment (creatinine clearance [CLcr] 30 to 89 mL/min, estimated by Cockcroft-Gault). The recommended dosage has not been established for patients with severe renal impairment (CLcr < 30 mL/min) [see Clinical Pharmacology (12.3) ].
Kidney rows of the label's dosage tables
From the TEPMETKO label (Apr 2025) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 691 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
163 of 691 reports
Reported with hospitalization
188 of 691 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tepotinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Verzenio · CDK4/6 inhibitor
Benign creatinine rise via tubular secretion block.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Voranigo · Mutant IDH1/2 inhibitor
A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.
Inluriyo · Oral selective estrogen-receptor degrader (SERD)
2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.